Trial ISRCTN69254139, EudraCT: 2020-005085-33
Publication Liu X, Lancet, 2021
Primary outcome on the report: Serum SARS-CoV-2 anti-spike IgG concentration at 28 days post boost for those with a prime-boost interval of 28 days in participants who were seronegative for COVID infection at baseline

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.